HCW Biologics announced it has closed a $26.25 million non-dilutive financing agreement backed by its intellectual property and royalty interests. According to the company, the transaction provides immediate capital without issuing additional equity.
The company said the financing was structured around its interest in royalties and milestone payments related to an out-licensed asset. HCW Biologics claims the proceeds will help fund clinical development, research programs and general corporate activities.
According to the company, the transaction strengthens its balance sheet and extends its cash runway as it advances its proprietary pipeline of immunotherapies targeting chronic inflammation and age-related diseases. HCW Biologics said its lead candidate, HCW9218, is in Phase 1b/2 trials for solid tumors and pancreatic cancer.
The company claims that by securing non-dilutive capital, it can continue to invest in research and development without diluting existing shareholders. Hcw Biologics said the financing aligns with its broader strategy to build long-term value through clinical progress and strategic partnerships.
According to the company, the new funding supports efforts to accelerate clinical studies and expand research into additional indications for its immunotherapeutic platforms. Hcw Biologics claims this financial move positions it to advance programs targeting inflammation-driven diseases linked to aging and cancer.
